US20030130209A1
(en)
*
|
1999-12-22 |
2003-07-10 |
Cheresh David A. |
Method of treatment of myocardial infarction
|
US20060258686A1
(en)
*
|
1998-05-29 |
2006-11-16 |
Cheresh David A |
Method of treatment of myocardial infarction
|
ATE494388T1
(de)
|
1999-01-13 |
2011-01-15 |
Univ New York State Res Found |
Neues verfahren zum erschaffen von proteinkinase- inhibitoren
|
US7223724B1
(en)
*
|
1999-02-08 |
2007-05-29 |
Human Genome Sciences, Inc. |
Use of vascular endothelial growth factor to treat photoreceptor cells
|
ATE253918T1
(de)
|
1999-12-08 |
2003-11-15 |
Centre Nat Rech Scient |
Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
|
US7273751B2
(en)
*
|
2000-08-04 |
2007-09-25 |
Human Genome Science, Inc. |
Vascular endothelial growth factor-2
|
MXPA03008560A
(es)
*
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
US20050232921A1
(en)
*
|
2001-04-13 |
2005-10-20 |
Rosen Craig A |
Vascular endothelial growth factor 2
|
EP1385862A4
(en)
*
|
2001-04-13 |
2005-03-02 |
Human Genome Sciences Inc |
VASCULAR ENDOTHEL GROWTH FACTOR 2
|
DK1385864T3
(da)
*
|
2001-04-13 |
2010-08-16 |
Human Genome Sciences Inc |
Anti-VEGF-2-antistoffer
|
US7005445B2
(en)
|
2001-10-22 |
2006-02-28 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors and methods for designing them
|
JP4623962B2
(ja)
*
|
2001-10-22 |
2011-02-02 |
ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク |
タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
|
US20030199525A1
(en)
*
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
MXPA05001389A
(es)
|
2002-08-06 |
2005-04-28 |
Astrazeneca Ab |
Piridinas y pirimidinas condensadas con actividad tie2 (tek).
|
JP2006516572A
(ja)
|
2003-01-14 |
2006-07-06 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
代謝モジュレーターとしての1,2,3−トリ置換アリール誘導体および1,2,3−トリ置換ヘテロアリール誘導体ならびにこれらの誘導体に関連する糖尿病および高血糖のような障害の予防および処置
|
JP4960085B2
(ja)
*
|
2003-03-19 |
2012-06-27 |
エクセリクシス, インク. |
Tie−2モジュレータと使用方法
|
WO2004100868A2
(en)
*
|
2003-04-23 |
2004-11-25 |
Abbott Laboratories |
Method of treating transplant rejection
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
JP4920410B2
(ja)
*
|
2003-07-14 |
2012-04-18 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療
|
DE10344223A1
(de)
*
|
2003-09-24 |
2005-04-21 |
Merck Patent Gmbh |
1,3-Benzoxazolylderivate als Kinase-Inhibitoren
|
GB0401334D0
(en)
*
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
WO2005074603A2
(en)
*
|
2004-02-03 |
2005-08-18 |
Abbott Laboratories |
Aminobenzoxazoles as therapeutic agents
|
JP2008520744A
(ja)
*
|
2004-11-19 |
2008-06-19 |
ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア |
抗炎症性ピラゾロピリミジン
|
DOP2006000009A
(es)
*
|
2005-01-13 |
2006-08-15 |
Arena Pharm Inc |
Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
|
MX369262B
(es)
*
|
2005-02-16 |
2019-11-04 |
Anacor Pharmaceuticals Inc |
Moleculas pequeñas que contienen boro.
|
WO2007029629A1
(ja)
*
|
2005-09-06 |
2007-03-15 |
Shionogi & Co., Ltd. |
Pgd2受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
|
PT1951724E
(pt)
|
2005-11-17 |
2011-08-02 |
Osi Pharm Inc |
Inibidores mtor fundidos bicíclicos
|
DK2348023T5
(da)
|
2005-12-13 |
2017-05-15 |
Incyte Holdings Corp |
Heteroaryl-substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus-kinase-inhibitorer
|
US7625880B2
(en)
*
|
2006-01-13 |
2009-12-01 |
Pharmacyclics, Inc. |
Inhibitors of tyrosine kinases and uses thereof
|
TW200738725A
(en)
*
|
2006-01-25 |
2007-10-16 |
Osi Pharm Inc |
Unsaturated mTOR inhibitors
|
EP2001880A2
(en)
|
2006-03-07 |
2008-12-17 |
Array Biopharma, Inc. |
Heterobicyclic pyrazole compounds and methods of use
|
KR20150038395A
(ko)
|
2006-04-04 |
2015-04-08 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
키나제 길항물질
|
TW200806637A
(en)
*
|
2006-05-25 |
2008-02-01 |
Synta Pharmaceuticals Corp |
Synthesis of triazole compounds that modulate HSP90 activity
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
US9060966B2
(en)
*
|
2006-08-16 |
2015-06-23 |
Pedro Cuevas Sánchez |
Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain
|
SI2526771T1
(sl)
|
2006-09-22 |
2017-06-30 |
Pharmacyclics Llc |
Inhibitorji Bruton tirozin kinaze
|
WO2008054827A2
(en)
*
|
2006-11-03 |
2008-05-08 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
WO2008070994A1
(en)
*
|
2006-12-14 |
2008-06-19 |
Nps Pharmaceuticals, Inc. |
Use of d-serine derivatives for the treatment of anxiety disorders
|
JP2010514692A
(ja)
|
2006-12-20 |
2010-05-06 |
バイエル ヘルスケア リミティド ライアビリティ カンパニー |
癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物
|
PL2099442T3
(pl)
*
|
2006-12-26 |
2015-04-30 |
Pharmacyclics Inc |
Sposób stosowania inhibitorów deacetylazy histonów i monitoringu biomarkerów w terapii skojarzonej
|
EP2125895B1
(en)
*
|
2007-02-02 |
2015-04-08 |
Vegenics Pty Ltd |
Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
WO2008153701A1
(en)
*
|
2007-05-24 |
2008-12-18 |
Schering Corporation |
Compounds for inhibiting ksp kinesin activity
|
RS53245B2
(sr)
|
2007-06-13 |
2022-10-31 |
Incyte Holdings Corp |
Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
|
US20110160232A1
(en)
|
2007-10-04 |
2011-06-30 |
Pingda Ren |
Certain chemical entities and therapeutic uses thereof
|
US20110038835A1
(en)
*
|
2007-12-21 |
2011-02-17 |
The Scripps Research Institute |
Anilides and analogs as rho kinase inhibitors
|
EP2234618A4
(en)
*
|
2007-12-21 |
2011-04-27 |
Scripps Research Inst |
BENZOPYRANE AND ANALOGUE AS RHO KINASE INHIBITORS
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
AU2009204483B2
(en)
|
2008-01-04 |
2014-03-13 |
Intellikine, Llc |
Certain chemical entities, compositions and methods
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
WO2009114870A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
BRPI0910232A2
(pt)
*
|
2008-03-19 |
2015-09-29 |
Osi Pharm Inc |
formas de sais inibidores do mtor
|
US20100101977A1
(en)
*
|
2008-06-05 |
2010-04-29 |
United Comb & Novelty Corporation |
Stackable Packaging For Lipped Containers
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
BRPI0915231A2
(pt)
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
CA2730930C
(en)
|
2008-07-16 |
2015-01-13 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
JP5731978B2
(ja)
|
2008-09-26 |
2015-06-10 |
インテリカイン, エルエルシー |
複素環キナーゼ阻害剤
|
JP5819195B2
(ja)
*
|
2008-10-16 |
2015-11-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
融合環ヘテロアリールキナーゼ阻害剤
|
CA2742306A1
(en)
*
|
2008-11-03 |
2010-05-06 |
Chemocentryx, Inc. |
Compounds for the treatment of osteoporosis and cancers
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
US8426428B2
(en)
*
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
EP2427195B1
(en)
|
2009-05-07 |
2019-05-01 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
AU2010249380B2
(en)
|
2009-05-22 |
2015-08-20 |
Incyte Holdings Corporation |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
|
EP2432472B1
(en)
|
2009-05-22 |
2019-10-02 |
Incyte Holdings Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
JP6073677B2
(ja)
|
2009-06-12 |
2017-02-01 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
縮合複素環式化合物およびそれらの使用
|
AU2010284254B2
(en)
|
2009-08-17 |
2015-09-17 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
EP2483406A2
(en)
|
2009-09-30 |
2012-08-08 |
President and Fellows of Harvard College |
Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
|
US7718662B1
(en)
*
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
CN105153188B
(zh)
|
2009-10-22 |
2018-06-01 |
法博太科制药有限公司 |
抗纤维化剂的稠环类似物
|
US20110130711A1
(en)
*
|
2009-11-19 |
2011-06-02 |
Follica, Inc. |
Hair growth treatment
|
CA2784807C
(en)
|
2009-12-29 |
2021-12-14 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
EP2528894A1
(en)
|
2010-01-27 |
2012-12-05 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
|
CA2789434A1
(en)
|
2010-02-11 |
2011-08-18 |
Vanderbilt University |
Benzisoxazoles and azabenzisoxazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
SI3354652T1
(sl)
*
|
2010-03-10 |
2020-08-31 |
Incyte Holdings Corporation |
Derivati piperidin-4-il azetidina kot inhibitorji JAK1
|
WO2011133520A1
(en)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
MY178634A
(en)
|
2010-05-21 |
2020-10-19 |
Incyte Corp |
Topical formulation for a jak inhibitor
|
CA2799579A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
US9096531B2
(en)
|
2010-05-24 |
2015-08-04 |
Toa Eiyo Ltd. |
Fused imidazole derivative
|
CA3154024C
(en)
|
2010-06-03 |
2024-02-27 |
Pharmacyclics Llc |
Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
|
AU2011276955B2
(en)
*
|
2010-07-09 |
2014-11-06 |
The Walter And Eliza Hall Institute Of Medical Research |
Protein kinase inhibitors and methods of treatment
|
CA2812061A1
(en)
|
2010-09-22 |
2012-03-29 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
JP2013545749A
(ja)
|
2010-11-10 |
2013-12-26 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環化合物及びその使用
|
JP5917545B2
(ja)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
|
SG10201600179RA
(en)
|
2011-01-10 |
2016-02-26 |
Infinity Pharmaceuticals Inc |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
EP2678018A4
(en)
|
2011-02-23 |
2015-09-30 |
Intellikine Llc |
COMBINATION OF CHINESE HEMMER AND USES THEREOF
|
EA201490042A1
(ru)
|
2011-06-20 |
2014-10-30 |
Инсайт Корпорейшн |
Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
|
US10465247B2
(en)
|
2011-07-01 |
2019-11-05 |
Dana-Farber Cancer Institute, Inc. |
Discovery of a somatic mutation in MYD88 gene in lymphoplasmacytic lymphoma
|
EA201490265A1
(ru)
|
2011-07-13 |
2014-12-30 |
Фармасайкликс, Инк. |
Ингибиторы тирозинкиназы брутона
|
US8969363B2
(en)
|
2011-07-19 |
2015-03-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CN106243113B
(zh)
|
2011-07-19 |
2018-12-18 |
默沙东有限责任公司 |
作为btk抑制剂的选择的咪唑并吡嗪类
|
AU2012284091B2
(en)
|
2011-07-19 |
2015-11-12 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
EP2548877A1
(en)
*
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
CA2846431A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
AU2011376953B2
(en)
|
2011-09-13 |
2017-08-24 |
Pharmacyclics Llc |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
EP2776025A1
(en)
|
2011-11-02 |
2014-09-17 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with platinum-containing agents
|
JP2014532712A
(ja)
|
2011-11-02 |
2014-12-08 |
シンタ ファーマシューティカルズ コーポレーション |
トポイソメラーゼi阻害剤とhsp90阻害剤の組合せを使用する癌療法
|
EP2780010A1
(en)
|
2011-11-14 |
2014-09-24 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
ES2619829T3
(es)
|
2011-11-18 |
2017-06-27 |
Heptares Therapeutics Limited |
Agonistas del receptor muscarínico M1
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
WO2013113097A1
(en)
*
|
2012-01-31 |
2013-08-08 |
Beta Pharma Canada Inc. |
Cyclic molecules as bruton's tyrosine kinase inhibitors
|
US9045403B2
(en)
|
2012-02-29 |
2015-06-02 |
Coyote Pharmaceuticals, Inc. |
Geranyl geranyl acetone (GGA) derivatives and compositions thereof
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AR091079A1
(es)
|
2012-05-18 |
2014-12-30 |
Incyte Corp |
Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
|
CA2874211A1
(en)
|
2012-05-31 |
2013-12-05 |
Pharmascience Inc. |
Protein kinase inhibitors
|
MY194911A
(en)
|
2012-06-04 |
2022-12-22 |
Pharmacyclics Llc |
Crystalline forms of a bruton's tyrosine kinase inhibitor
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
GB201211309D0
(en)
*
|
2012-06-26 |
2012-08-08 |
Fujifilm Mfg Europe Bv |
Process for preparing membranes
|
MX2015001081A
(es)
|
2012-07-24 |
2015-10-14 |
Pharmacyclics Inc |
Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
|
JP6327713B2
(ja)
*
|
2012-07-27 |
2018-05-23 |
国立研究開発法人理化学研究所 |
急性骨髄性白血病の治療又は再発抑制剤
|
KR20150061651A
(ko)
|
2012-09-26 |
2015-06-04 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Ire1의 조절
|
US9119808B1
(en)
|
2012-10-08 |
2015-09-01 |
Coyote Pharmaceuticals, Inc. |
Treating neurodegenerative diseases with GGA or a derivative thereof
|
WO2014063068A1
(en)
|
2012-10-18 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
USRE48175E1
(en)
*
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
PE20151495A1
(es)
|
2012-11-15 |
2015-10-23 |
Pharmacyclics Inc |
Compuestos de pirrolopirimidina como inhibidores de quinasas
|
WO2014078486A1
(en)
|
2012-11-15 |
2014-05-22 |
Incyte Corporation |
Sustained-release dosage forms of ruxolitinib
|
WO2014113942A1
(en)
*
|
2013-01-23 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
EP2953940B1
(en)
|
2013-02-07 |
2018-08-22 |
Heptares Therapeutics Limited |
Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic m4 receptor agonists
|
CA2902263A1
(en)
|
2013-03-06 |
2014-09-12 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
KR102366356B1
(ko)
|
2013-03-06 |
2022-02-23 |
인사이트 홀딩스 코포레이션 |
Jak 저해제를 제조하기 위한 방법 및 중간생성물
|
TWI629275B
(zh)
*
|
2013-03-13 |
2018-07-11 |
賽諾菲公司 |
N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014153509A1
(en)
|
2013-03-22 |
2014-09-25 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
EP3027192A4
(en)
|
2013-08-02 |
2017-03-22 |
Pharmacyclics, LLC |
Methods for the treatment of solid tumors
|
PE20220579A1
(es)
|
2013-08-07 |
2022-04-20 |
Incyte Corp |
Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1
|
CA2920534A1
(en)
|
2013-08-12 |
2015-02-19 |
Pharmacyclics Llc |
Methods for the treatment of her2 amplified cancer
|
BR112016006978A2
(pt)
|
2013-09-30 |
2017-08-01 |
Pharmacyclics Llc |
inibidores de tirosina quinase de bruton
|
MY175778A
(en)
|
2013-10-04 |
2020-07-08 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US20160264551A1
(en)
|
2013-10-18 |
2016-09-15 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
JP6491202B2
(ja)
|
2013-10-18 |
2019-03-27 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
サイクリン依存性キナーゼ7(cdk7)の多環阻害剤
|
EA201690745A1
(ru)
|
2013-10-25 |
2016-11-30 |
Фармасайкликс Элэлси |
Способы лечения и предотвращения болезни "трансплантат против хозяина"
|
EP3076974A1
(en)
|
2013-12-05 |
2016-10-12 |
Acerta Pharma B.V. |
Therapeutic combination of a pi3k inhibitor and a btk inhibitor
|
US10272083B2
(en)
|
2014-01-21 |
2019-04-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
|
EA201691302A1
(ru)
*
|
2014-02-03 |
2017-03-31 |
Кадила Хелзкэр Лимитед |
Новые гетероциклические соединения
|
CN114404427A
(zh)
|
2014-02-13 |
2022-04-29 |
配体药物公司 |
前药化合物及其用途
|
SG11201607705XA
(en)
|
2014-03-19 |
2016-10-28 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
CA2942528A1
(en)
|
2014-03-20 |
2015-09-24 |
Pharmacyclics Inc. |
Phospholipase c gamma 2 and resistance associated mutations
|
US9937171B2
(en)
|
2014-04-11 |
2018-04-10 |
Acerta Pharma B.V. |
Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
US10017477B2
(en)
|
2014-04-23 |
2018-07-10 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
WO2015191986A1
(en)
|
2014-06-13 |
2015-12-17 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
WO2015193740A2
(en)
|
2014-06-17 |
2015-12-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
|
CA2959602A1
(en)
|
2014-08-01 |
2016-02-04 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
JP2017523206A
(ja)
|
2014-08-07 |
2017-08-17 |
ファーマサイクリックス エルエルシー |
ブルトン型チロシンキナーゼ阻害剤の新規製剤
|
LT3179991T
(lt)
|
2014-08-11 |
2021-11-10 |
Acerta Pharma B.V. |
Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP3221320A4
(en)
*
|
2014-11-19 |
2018-04-25 |
Sun Pharmaceutical Industries Ltd |
A process for the preparation of ibrutinib
|
AU2015371251B2
(en)
|
2014-12-23 |
2020-06-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
WO2016106628A1
(en)
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
EP3242666A1
(en)
|
2015-01-06 |
2017-11-15 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the s1p1 receptor
|
CN105481862B
(zh)
*
|
2015-01-21 |
2018-08-21 |
中国科学院合肥物质科学研究院 |
Flt3激酶的新型抑制剂及其用途
|
WO2016115869A1
(zh)
*
|
2015-01-21 |
2016-07-28 |
中国科学院合肥物质科学研究院 |
Flt3激酶的新型抑制剂及其用途
|
WO2016141068A1
(en)
|
2015-03-03 |
2016-09-09 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
|
MA41828A
(fr)
*
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
WO2016161248A1
(en)
*
|
2015-04-02 |
2016-10-06 |
Tolero Pharmaceuticals, Inc. |
Targeting pim kinases in combination with btk inhibition
|
CA2986441A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
CN108349891B
(zh)
|
2015-06-22 |
2022-04-05 |
艾尼纳制药公司 |
用于s1p1受体相关病症的化合物的结晶l-精氨酸盐
|
MA50817B1
(fr)
|
2015-07-02 |
2021-10-29 |
Acerta Pharma Bv |
Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
|
JP7028766B2
(ja)
|
2015-09-09 |
2022-03-02 |
ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
KR20180058741A
(ko)
|
2015-09-14 |
2018-06-01 |
인피니티 파마슈티칼스, 인코포레이티드 |
이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
|
WO2017046604A1
(en)
|
2015-09-16 |
2017-03-23 |
Redx Pharma Plc |
Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
|
CO2018006164A2
(es)
|
2015-12-16 |
2018-09-20 |
Loxo Oncology Inc |
Compuestos útiles como inhibidores de cinasa
|
US10793566B2
(en)
|
2016-01-21 |
2020-10-06 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
CN109310671B
(zh)
|
2016-01-21 |
2021-08-06 |
淄博百极常生制药有限公司 |
布鲁顿酪氨酸激酶抑制剂
|
US10435396B2
(en)
|
2016-03-03 |
2019-10-08 |
Bayer Pharma Aktiegesellschaft |
2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
|
CN109071455B
(zh)
|
2016-03-11 |
2022-08-02 |
嘉兴和剂药业有限公司 |
用于调节布鲁顿酪氨酸激酶的化合物及方法
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
US10525060B2
(en)
|
2016-04-29 |
2020-01-07 |
Dana-Farber Cancer Institute, Inc. |
HCK as a therapeutic target in MYD88 mutated diseases
|
CN105820184A
(zh)
*
|
2016-05-06 |
2016-08-03 |
蚌埠中实化学技术有限公司 |
一种4-苯氧基苯硼酸的制备方法
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
MX2018016227A
(es)
|
2016-06-24 |
2019-07-08 |
Infinity Pharmaceuticals Inc |
Terapias de combinacion.
|
GB201617454D0
(en)
|
2016-10-14 |
2016-11-30 |
Heptares Therapeutics Limited |
Pharmaceutical compounds
|
CA3047586A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas Operations, Inc. |
Egfr proteolysis targeting chimeric molecules and associated methods of use
|
US11014873B2
(en)
|
2017-02-03 |
2021-05-25 |
Certa Therapeutics Pty Ltd. |
Anti-fibrotic compounds
|
US11534424B2
(en)
|
2017-02-16 |
2022-12-27 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of primary biliary cholangitis
|
CA3065309A1
(en)
|
2017-06-01 |
2018-12-06 |
Bristol-Myers Squibb Company |
Substituted nitrogen containing compounds
|
JP2020530844A
(ja)
|
2017-08-14 |
2020-10-29 |
エピザイム,インコーポレイティド |
Setd2を阻害することにより癌を処置する方法
|
CN107550905B
(zh)
*
|
2017-09-11 |
2020-07-17 |
浙江永宁药业股份有限公司 |
多取代吡咯并吡啶类化合物的药物用途及其制备方法
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
CN111699031B
(zh)
*
|
2017-12-27 |
2022-10-28 |
株式会社新生能源研究 |
Co2除去方法和装置
|
EP4086245A1
(en)
|
2018-01-30 |
2022-11-09 |
Incyte Corporation |
Processes for preparing intermediates for the synthesis of a jak inhibitor
|
SG11202009441PA
(en)
|
2018-03-30 |
2020-10-29 |
Incyte Corp |
Treatment of hidradenitis suppurativa using jak inhibitors
|
GB201810239D0
(en)
|
2018-06-22 |
2018-08-08 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
WO2020079652A1
(en)
|
2018-10-17 |
2020-04-23 |
Insilico Medicine Hong Kong Limited |
Kinase inhibitors
|
BR112021009106A2
(pt)
|
2018-11-12 |
2021-08-10 |
Debiopharm International S.A. |
compostos antibióticos, métodos de fabricação dos mesmos, composições farmacêuticas que os contêm e seus usos
|
GB201819960D0
(en)
|
2018-12-07 |
2019-01-23 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
CN111454268B
(zh)
*
|
2019-01-18 |
2023-09-08 |
明慧医药(上海)有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
SG11202109194UA
(en)
*
|
2019-02-27 |
2021-09-29 |
Optikira Llc |
Pyrazolopyridine compounds for ire1 inhibition
|
EP3978496A4
(en)
|
2019-05-31 |
2022-08-17 |
Haisco Pharmaceuticals Pte. Ltd. |
BTK INHIBITOR RING DERIVATIVES, METHOD OF MANUFACTURE THEREOF AND PHARMACEUTICAL USE THEREOF
|
CN110511225B
(zh)
*
|
2019-08-19 |
2023-07-18 |
杭州中美华东制药有限公司 |
一种伊布替尼中间体的合成方法
|
WO2021038540A1
(en)
|
2019-08-31 |
2021-03-04 |
Sun Pharma Advanced Research Company Limited |
Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
|
AU2020436612A1
(en)
*
|
2020-03-16 |
2022-09-01 |
Flash Therapeutics, Llc |
Compounds for treating or inhibiting recurrence of acute myeloid leukemia
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2022081512A1
(en)
*
|
2020-10-12 |
2022-04-21 |
Synubi Pharmaceuticals Llc |
Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
|
MX2023005747A
(es)
|
2020-11-18 |
2023-07-28 |
Deciphera Pharmaceuticals Llc |
Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
|
CN114751927B
(zh)
*
|
2022-03-08 |
2023-10-31 |
中山大学 |
一种硼酸化合物、制备方法及用途
|
CN115124486A
(zh)
*
|
2022-07-07 |
2022-09-30 |
武汉理工大学 |
苯并噁唑衍生物及其制备方法与应用
|